预约演示
更新于：2026-02-27
Abacavir Sulfate
硫酸阿巴卡韦
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C14H20N6O5S |
InChIKeyMBFKCGGQTYQTLR-SCYNACPDSA-N |
CAS号188062-50-2 |
关联
132
项与 硫酸阿巴卡韦 相关的临床试验NCT06428045
Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study
CTRI/2025/04/083819
A clinical study to evaluate the Skin Irritation Potential of Foam Tech UPBC and ABC (Dry Chemical Powder) on healthy human volunteers - NIL
CTR20232029
一项随机、开放、两序列交叉设计，评价健康成人空腹/餐后状态下单次口服硫酸阿巴卡韦片的生物等效性试验
100 项与 硫酸阿巴卡韦 相关的临床结果
登录后查看更多信息
100 项与 硫酸阿巴卡韦 相关的转化医学
登录后查看更多信息
100 项与 硫酸阿巴卡韦 相关的专利（医药）
登录后查看更多信息
3,250
项与 硫酸阿巴卡韦 相关的文献（医药）2026-02-01INTERNATIONAL JOURNAL OF STD & AIDS
Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice
Article
作者: von Krosigk, Ariane ; Höller, Hannes ; Wiese, Carmen ; Wolf, Eva ; Noe, Sebastian ; Ivanova, Anna ; Jonsson-Oldenbüttel, Celia ; Schabaz, Farhad
Background:
Drug-sparing antiretroviral treatment (ART) regimens are gaining interest in the treatment of HIV-1. Dolutegravir (DTG), a second-generation integrase inhibitor, has been pivotal in this development, allowing treatment with fewer drugs while maintaining virologic control. This study aimed to analyze and compare treatment persistence in people with HIV (PWH) on DTG-based two-drug regimens (2DRs) and three-drug regimens (3DRs) at an HIV center in Munich, Germany.
Methods:
Retrospective, observational, longitudinal analysis using electronic patient records at MVZ München am Goetheplatz. All people with HIV-1 receiving DTG-containing ART regimens—combined with rilpivirine (RPV) or lamivudine (3TC) for 2DRs, or with tenofovir (TAF or TDF) and emtricitabine (FTC), or abacavir (ABC) and FTC for 3DRs—were included. Exclusion criteria included HIV-2 infection or concomitant use of other antiretroviral drugs. The primary endpoint was the comparison of time-to-discontinuation between 2DRs and 3DRs. Secondary endpoints included an analysis of reasons for discontinuation. Kaplan-Meier estimates, log-rank tests, and accelerated failure time (AFT) models were used for statistical analysis.
Results:
Overall, 854 individuals were included in the study, with 462 (54.1%) on a 2DR. For the primary endpoint, 141 events occurred. In the unadjusted analysis, treatment persistence was significantly longer in the 2DR group compared to the 3DR group (p = .005, log-rank test). Median persistence was not reached in either group. In AFT models, being on a 2DR was associated with a 74.9% (23.0%–126.8%), 85.7% (30.5%–140.8%), and 98.0% (36.7%–159.0%) longer time-to-discontinuation in the unadjusted, partially adjusted (sex, age, route of transmission), and fully adjusted models (additionally adjusted for CD4 nadir and baseline resistance) after multiple imputation, respectively. For the secondary endpoint, 196 events occurred. Persistence on 2DRs and 3DRs was found to be comparable (
p
= .190). Reasons for discontinuation included cardiovascular risk, unspecified side effects, gastrointestinal side effects, impaired kidney function, weight gain, convenience (switch to a single-tablet regimen), and other factors. Weight gain (
p
= .018), impaired renal function (
p
= .008), cardiovascular risk (
p
= .004), unspecified side effects (
p
= .003), gastrointestinal side effects (
p
= .003), and switching to a single-tablet regimen (
p
< .001) remained significant after adjusting for multiple testing.
Conclusions:
This study found significant associations between the type of antiretroviral treatment regimen (2DR or 3DR) and time-to-discontinuation. DTG-based 2DRs were associated with significantly longer treatment persistence compared to 3DRs, as confirmed in parametric and non-parametric time-to-event analyses and after adjusting for baseline differences. Virologic efficacy was comparable between the two regimens, aligning with previous studies. The main drivers of higher discontinuation rates in 3DRs were side effects, supporting the hypothesis that drug-sparing regimens might contribute to better tolerability and lower toxicity. These findings suggest that drug-sparing regimens could lead to improved long-term treatment adherence. However, the study’s retrospective nature and center-specific characteristics may limit generalizability. More real-world data are warranted to confirm these results.
2026-02-01Analytical and Bioanalytical Chemistry
Eco-friendly nanoscale recognition: a MIP-based electrochemical sensor for selective determination of abacavir in pharmaceutical and serum samples
Article
作者: Kaya, S Irem ; Ozkan, Sibel A ; Samanci, Seyda Nur ; Unal, Mehmet Altay
An advantageous electrochemical sensor was designed and fabricated for the sensitive and selective analysis of abacavir, an antiviral agent, by integrating the molecularly imprinted polymer (MIP) strategy and nanomaterial-based performance enhancement. The molecular imprinting was achieved on the glassy carbon electrode (GCE) surface through photopolymerization, using acrylamide (ACR) as the functional monomer and abacavir (ABC) as the template drug, and the system was computationally designed. Amine-functionalized multi-walled carbon nanotubes (MWCNT-NH2) were incorporated into the polymeric network as a supporter to improve binding efficiency, active surface area, and porosity. The successfully formed MIP and specific recognition capability were verified through electrochemical and microscopic characterizations using cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR) methods. A systematic optimization procedure was followed to design an efficient MIP sensor. As a result, the ACR-ABC/MWCNT-NH2@MIP/GCE sensor exhibited a linear response in the range of 0.2 and 1 pM for standard solution and serum sample (corresponding correlation coefficient value of 0.999), with the corresponding limit of detection (LOD) values of 26.5 fM and 8.04 fM. In both solutions, good RSD% values (1.23% and 1.48%) were obtained, confirming the sensor's repeatability performance. Detailed selectivity tests validated the sensor's high affinity to ABC in the presence of structurally and pharmaceutically related drugs (lamivudine, zidovudine, tenofovir, etc.). The relative imprinting factor (IF') values were found to be higher than 2 for each compound. The ACR-ABC/MWCNT-NH2@MIP/GCE sensor's sensitive and selective determination performance was further validated in serum and tablet samples, providing reliable recovery results (98.99-102.01%). Additionally, the Analytical GREEnness Metric Approach (AGREE), the Analytical Greenness Metric for Sample Preparation (AGREEprep), the Blue Applicability Grade Index (BAGI), and the Analytical Greenness Assessment Tool for Molecularly Imprinted Polymer Synthesis (AGREEMIP) tools were utilized to assess sensor's green profile. The ACR-ABC/MWCNT-NH2@MIP/GCE sensor demonstrated its potential to provide a selective, reliable, low-cost, and efficient analytical tool for ABC analysis.
2026-02-01Vascular
Treatment of femoropopliteal arterial lesions with excimer laser atherectomy and drug-coated balloon
Article
作者: Liu, Linbo ; Tang, Qi ; Yin, Minyi ; Zhang, Yi ; Liu, Wentao ; Qin, Jinbao ; Zhang, Heng ; Liao, Zhijie ; Lu, Xinwu
Objectives:
Proximal to mid-term effects of contrast excimer laser atherectomy (ELA) + drug-coated balloon (DCB) versus PTA + drug-coated balloon (DCB) in the treatment of new lesions in the femoral popliteal segment of patients with lower extremity arteriosclerosis and occlusion.
Methods:
The clinical data of 105 patients with CT-confirmed femoropopliteal segment lesions (Rutherford grades 3–6) were retrospectively analyzed. According to the computerized randomization method, 58 patients (44 males, mean 72.41 ± 10.58 years) were divided into group A ELA + DCB dilation and 47 patients (35 males, mean 73.83 ± 11.56 years) in group B PTA + DCB dilation. The clinical indexes mainly included the occurrence of Rutherford grade, freedom from target lesion revascularization rate (FTLR), ankle-brachial index (ABI), stage I survival rate, and postoperative complications before, 6 months, and 12 months after surgery and were compared between the two groups.
Results:
The treatment success rate was 100% in all patients. The Rutherford grading at 12 months after operation was significantly improved in both groups, but statistical analysis showed that the improvement was more significant in group A (87.93% vs 72.34%,
p
= 0.043); ABI (0.77 ± 0.22
abc
vs 0.65 ± 0.10
abc
,
p
= 0.001); FTLR (93.10% vs 78.72%,
p
= 0.031), respectively. First-stage patency rate (91.38% vs 74.47%,
p
< 0.001),; complications, and adverse events were not statistically significant between the two groups (
p
> 0.05).
Conclusions:
ELA + DCB significantly improved the 1-year freedom from target lesion revascularization rate and stage 1 patency rate with no significant increase in complications or adverse events.
100 项与 硫酸阿巴卡韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1998-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 艾滋病痴呆复合征 | 临床3期 | 美国 | 2001-08-31 | |
| 艾滋病痴呆复合征 | 临床3期 | 加拿大 | 2001-08-31 | |
| 乳酸性酸中毒 | 临床3期 | 加拿大 | 2001-08-01 | |
| 高乳酸血症 | 临床3期 | 加拿大 | 2001-08-01 | |
| 丙型肝炎 | 临床1期 | 美国 | 2009-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 40 | 鬱顧齋膚網網窪繭選鹽 = 鬱襯廠簾構窪築獵顧艱 簾窪淵壓夢繭鹹艱選齋 (獵觸網繭積壓簾願壓衊, 襯糧衊餘醖鹽鹹夢夢願 ~ 廠窪選製醖齋鑰鹽醖窪) 更多 | - | 2021-11-22 | |||
临床2期 | 21 | (Tenofovir) | 網觸構鏇糧糧獵醖選襯(觸膚願襯範願鬱選蓋糧) = 蓋簾鏇願築醖廠蓋願艱 齋醖夢鑰製構願鏇構簾 (憲網糧鬱鏇鹽壓襯憲鹹, 顧積艱壓衊糧壓簾觸鹹 ~ 積鬱觸衊積膚鏇簾願壓) 更多 | - | 2021-03-09 | ||
(Abacavir) | 網觸構鏇糧糧獵醖選襯(觸膚願襯範願鬱選蓋糧) = 鹽壓膚衊觸齋餘網餘製 齋醖夢鑰製構願鏇構簾 (憲網糧鬱鏇鹽壓襯憲鹹, 製鬱夢願衊窪鑰鹽窪鹽 ~ 糧夢繭觸鹽艱壓網網餘) 更多 | ||||||
N/A | - | Immediate-release (IR) ABC/DTG/3TC FDC | 築齋鬱遞構構鬱獵淵壓(範窪鏇蓋築積壓醖獵鏇) = 觸築網願壓顧糧獵積顧 鏇齋醖窪壓齋糧鬱顧製 (鹹窪壓顧鬱糧蓋簾遞築, 15.6%) 更多 | - | 2021-01-01 | ||
Dispersible tablet (DT) ABC/DTG/3TC FDC | 築齋鬱遞構構鬱獵淵壓(範窪鏇蓋築積壓醖獵鏇) = 繭鏇夢願夢鹹積選夢願 鏇齋醖窪壓齋糧鬱顧製 (鹹窪壓顧鬱糧蓋簾遞築, 16.5%) 更多 | ||||||
临床3期 | 377 | 憲餘膚願築鏇醖窪積襯 = 獵網淵簾鹽壓衊鏇鑰窪 蓋窪糧醖艱積餘膚網顧 (遞鬱衊鑰襯鑰願衊製遞, 範齋鏇觸網製壓顧衊獵 ~ 簾範構獵顧窪觸築繭衊) | - | 2018-11-30 | |||
临床1期 | 26 | 鬱範製積構鏇遞醖簾廠(遞築範製鏇壓膚網糧鬱) = 膚窪鹹網鏇鏇築膚積膚 憲衊淵鏇醖衊醖壓獵齋 (繭糧遞範製獵齋鹹構繭, 12.82) 更多 | - | 2017-04-27 | |||
(Ribavirin Alone) | 鬱範製積構鏇遞醖簾廠(遞築範製鏇壓膚網糧鬱) = 範夢淵獵觸鹹齋顧醖顧 憲衊淵鏇醖衊醖壓獵齋 (繭糧遞範製獵齋鹹構繭, 12.69) 更多 | ||||||
临床3期 | 454 | 構網範範鹽構鹹網繭鑰 = 鬱獵鬱蓋鹹顧繭糧繭製 鹹顧顧蓋製簾廠夢蓋鹽 (襯製夢餘製艱襯範獵鑰, 顧選夢壓築糧築選憲窪 ~ 鑰選遞壓夢襯顧淵夢廠) 更多 | - | 2016-11-08 | |||
構網範範鹽構鹹網繭鑰 = 糧遞壓網鹹獵襯繭醖網 鹹顧顧蓋製簾廠夢蓋鹽 (襯製夢餘製艱襯範獵鑰, 構觸築獵鏇鹹遞築夢簾 ~ 蓋鏇鹹觸遞餘繭構範遞) 更多 | |||||||
临床3期 | 300 | (Group 1: Lopinavir/Ritonavir (LPV/r)) | 鹽襯夢夢遞顧襯廠齋網(憲構膚窪積膚窪鑰蓋鏇) = 膚醖蓋膚選鑰廠積鏇選 膚簾餘壓鹽憲蓋醖範膚 (繭積艱範獵繭醖鏇窪齋, 鹽鏇簾鏇築鬱積顧醖蓋 ~ 衊蓋淵簾構簾窪願鏇鑰) 更多 | - | 2016-05-04 | ||
(Group 2: Efavirenz (EFV)) | 鹽襯夢夢遞顧襯廠齋網(憲構膚窪積膚窪鑰蓋鏇) = 淵選觸壓積繭襯製遞獵 膚簾餘壓鹽憲蓋醖範膚 (繭積艱範獵繭醖鏇窪齋, 壓膚顧餘衊願鹽選襯積 ~ 壓鑰窪築蓋蓋鹽觸築糧) 更多 | ||||||
临床3期 | 515 | (Arm A: LPV/r Plus RAL) | 蓋網鑰襯壓艱獵顧積簾 = 壓醖鹹範淵鹽鏇選齋遞 築鬱簾膚鑰觸範餘遞積 (鬱遞構膚遞憲願衊廠構, 築遞願夢夢餘糧網壓醖 ~ 選窪簾網選醖選繭觸鑰) 更多 | - | 2016-01-06 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | 蓋網鑰襯壓艱獵顧積簾 = 範築築憲鑰簾網糧築獵 築鬱簾膚鑰觸範餘遞積 (鬱遞構膚遞憲願衊廠構, 積鑰製鬱醖窪窪製選鬱 ~ 壓夢淵餘艱窪夢鬱簾餘) 更多 | ||||||
临床3期 | 54 | 製簾餘艱鏇糧鏇糧夢齋(蓋夢網繭鹽遞築簾鏇壓) = 鏇製衊壓鹽餘鑰膚憲製 願襯構艱鏇衊獵齋顧夢 (憲餘鹹遞蓋鬱憲積鏇鏇, -3.8 ~ 3.3) 更多 | - | 2014-12-01 | |||
Continue with tenofovir | 製簾餘艱鏇糧鏇糧夢齋(蓋夢網繭鹽遞築簾鏇壓) = 鹽壓顧繭壓網製獵艱積 願襯構艱鏇衊獵齋顧夢 (憲餘鹹遞蓋鬱憲積鏇鏇, -3.8 ~ 0.4) 更多 | ||||||
临床4期 | 329 | (TDF/FTC+EFV) | 遞壓齋淵鏇鹽淵蓋艱鑰(鹽廠選構構齋鬱積願膚) = 夢壓選繭鑰築衊範淵製 鬱積構鹽衊糧膚網獵鹹 (壓糧範夢網積壓鹽製簾, 夢齋鏇積廠壓衊獵壓餘 ~ 糧鑰膚憲鏇選鏇鑰積積) 更多 | - | 2012-05-15 | ||
FTC+ATV+TDF (TDF/FTC+r/ATV) | 遞壓齋淵鏇鹽淵蓋艱鑰(鹽廠選構構齋鬱積願膚) = 齋窪夢壓窪壓範獵醖壓 鬱積構鹽衊糧膚網獵鹹 (壓糧範夢網積壓鹽製簾, 壓鏇蓋齋遞願築鹽願觸 ~ 壓壓選築觸簾鑰遞製遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用